CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,333,672 | -24.6% | 411,834 | -7.0% | 0.00% | -33.3% |
| Q2 2023 | $15,027,597 | +16.0% | 442,900 | +23.0% | 0.00% | 0.0% |
| Q1 2023 | $12,959,024 | -35.3% | 360,173 | -19.9% | 0.00% | -25.0% |
| Q4 2022 | $20,037,959 | +7.3% | 449,584 | -32.3% | 0.00% | 0.0% |
| Q3 2022 | $18,677,000 | +57.5% | 664,431 | +51.1% | 0.00% | +33.3% |
| Q2 2022 | $11,855,000 | +14.7% | 439,712 | +44.9% | 0.00% | +50.0% |
| Q1 2022 | $10,335,000 | +5.2% | 303,419 | +19.4% | 0.00% | 0.0% |
| Q4 2021 | $9,823,000 | -40.9% | 254,214 | -17.4% | 0.00% | -50.0% |
| Q3 2021 | $16,612,000 | +46.9% | 307,679 | -9.0% | 0.00% | +33.3% |
| Q2 2021 | $11,305,000 | +17.0% | 338,055 | -27.9% | 0.00% | +50.0% |
| Q1 2021 | $9,659,000 | -14.2% | 468,881 | -27.0% | 0.00% | -33.3% |
| Q4 2020 | $11,253,000 | +635.0% | 642,303 | +522.0% | 0.00% | – |
| Q3 2020 | $1,531,000 | – | 103,257 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |